In summary, in this large clinical trial, conducted in a real-world setting in a representative population of African malaria patients, pyronaridine–artesunate had excellent tolerability, safety, and effectiveness, and no clinically evident hepatic events occurred in patients with or without ALT/AST elevations at baseline. This evidence concerns the gene GPT and malaria.